Joshua R. Sacher

Joshua R. Sacher

Auto-generated profile, based on publicly available information

Joshua R. Sacher

Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge MA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2016 in ACS Central Science
Verified
Journal Article
Open access
TKTanja Krainz
Tanja Krainz
MGMichael M. Gaschler
Michael M. Gaschler
CLChaemin Lim
Chaemin Lim
JSJoshua R. Sacher
Joshua R. Sacher
BSBrent R. Stockwell
Brent R. Stockwell
PWPeter Wipf
Peter Wipf
Discovering compounds and mechanisms for inhibiting ferroptosis, a form of regulated, nonapoptotic cell death, has been of great interest in recent years. In this study, we demonstrate the ability of XJB-5-131, JP4-039, and other nitroxide-based lipid peroxidation mitigators to prevent ferroptotic cell death in HT-1080, BJeLR, and panc-1 cells. Several analogues of the reactive oxygen species (ROS) scavengers XJB-5-131 and JP4-039 were synthesized to probe structure–activity relationships and the influence of subcellular localization on the potency of these novel ferroptosis suppressors. Their biological activity correlated well over several orders of magnitude with their structure, relative lipophilicity, and respective enrichment in mitochondria, revealing a critical role of intramitochondrial lipid peroxidation in ferroptosis. These results also suggest that preventing mitochondrial lipid oxidation might offer a viable therapeutic opportunity in ischemia/reperfusion-induced tissue injury, acute kidney injury, and other pathologies that involve ferroptotic cell death pathways.

1 April 2019 in Cancer Cell
Verified
Journal Article
Closed access
LHLaura Hinze
Laura Hinze
MPMaren Pfirrmann
Maren Pfirrmann
SKSalmaan Karim
Salmaan Karim
JDJames Degar
James Degar
CMConnor McGuckin
Connor McGuckin
AGAlejandro Gutierrez
Alejandro Gutierrez

7 March 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
FWFlorence F. Wagner
Florence F. Wagner
LBLina Benajiba
Lina Benajiba
ACArthur J. Campbell
Arthur J. Campbell
MWMichel Weïwer
Michel Weïwer
JSJoshua R. Sacher
Joshua R. Sacher
EHEdward B. Holson
Edward B. Holson
Glycogen synthase kinase 3 (GSK3), a key regulatory kinase in the wingless-type MMTV integration site family (WNT) pathway, is a therapeutic target of interest in many diseases. Although dual GSK3α/β inhibitors have entered clinical trials, none has successfully translated to clinical application. Mechanism-based toxicities, driven in part by the inhibition of both GSK3 paralogs and subsequent β-catenin stabilization, are a concern in the translation of this target class because mutations and overexpression of β-catenin are associated with many cancers. Knockdown of GSK3α or GSK3β individually does not increase β-catenin and offers a conceptual resolution to targeting GSK3: paralog-selective inhibition. However, inadequate chemical tools exist. The design of selective adenosine triphosphate (ATP)–competitive inhibitors poses a drug discovery challenge due to the high homology (95% identity and 100% similarity) in this binding domain. Taking advantage of an Asp133→Glu196 “switch” in their kinase hinge, we present a rational design strategy toward the discovery of paralog-selective GSK3 inhibitors. These GSK3α- and GSK3β-selective inhibitors provide insights into GSK3 targeting in acute myeloid leukemia (AML), where GSK3α was identified as a therapeutic target using genetic approaches. The GSK3α-selective compound BRD0705 inhibits kinase function and does not stabilize β-catenin, mitigating potential neoplastic concerns. BRD0705 induces myeloid differentiation and impairs colony formation in AML cells, with no apparent effect on normal hematopoietic cells. Moreover, BRD0705 impairs leukemia initiation and prolongs survival in AML mouse models. These studies demonstrate feasibility of paralog-selective GSK3α inhibition, offering a promising therapeutic approach in AML.

1 December 2014 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
NENelson Escobales
Nelson Escobales
RNRebeca E. Nuñez
Rebeca E. Nuñez
SJSehwan Jang
Sehwan Jang
RPRebecca Parodi-Rullan
Rebecca Parodi-Rullan
SASylvette Ayala-Peña
Sylvette Ayala-Peña
Sabzali JavadovSabzali Javadov
Sabzali Javadov

13 May 2016 in ACS Chemical Biology
Verified
Journal Article
Closed access
FWFlorence F. Wagner
Florence F. Wagner
JBJoshua A. Bishop
Joshua A. Bishop
JGJennifer P. Gale
Jennifer P. Gale
XSXi Shi
Xi Shi
MWMichelle Walk
Michelle Walk
JPJen Q. Pan
Jen Q. Pan

1 November 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LHLaura Hinze
Laura Hinze
RLRoxane Labrosse
Roxane Labrosse
JDJames Degar
James Degar
THTeng Han
Teng Han
ESEmma M. Schatoff
Emma M. Schatoff
AGAlejandro Gutierrez
Alejandro Gutierrez
Colorectal cancer is driven by mutations that activate canonical WNT/β-catenin signaling, but inhibiting WNT has significant on-target toxicity, and there are no approved therapies targeting dominant oncogenic drivers. We recently found that activating a β-catenin–independent branch of WNT signaling that inhibits GSK3-dependent protein degradation induces asparaginase sensitivity in drug-resistant leukemias. To test predictions from our model, we turned to colorectal cancer because these cancers can have WNT-activating mutations that function either upstream (i.e., R-spondin fusions) or downstream (APC or β-catenin mutations) of GSK3, thus allowing WNT/β-catenin and WNT-induced asparaginase sensitivity to be unlinked genetically. We found that asparaginase had little efficacy in APC or β-catenin–mutant colorectal cancer, but was profoundly toxic in the setting of R-spondin fusions. Pharmacologic GSK3α inhibition was sufficient for asparaginase sensitization in APC or β-catenin–mutant colorectal cancer, but not in normal intestinal progenitors. Our findings demonstrate that WNT-induced therapeutic vulnerabilities can be exploited for colorectal cancer therapy. Significance: Solid tumors are thought to be asparaginase-resistant via de novo asparagine synthesis. In leukemia, GSK3α-dependent protein degradation, a catabolic amino acid source, mediates asparaginase resistance. We found that asparaginase is profoundly toxic to colorectal cancers with WNT-activating mutations that inhibit GSK3. Aberrant WNT activation can provide a therapeutic vulnerability in colorectal cancer. See related commentary by Davidsen and Sullivan, p. 1632. This article is highlighted in the In This Issue feature, p. 1611